Trial: Relacorilant aids survival in platinum-resistant ovarian cancer
Adding relacorilant to standard chemotherapy was shown to extend survival among people with platinum-resistant ovarian cancer, meeting the primary endpoint, or goal, of a…
News
CAR T-cell therapy successfully treats myeloma in Hong Kong
A CAR T-cell therapy manufactured in mainland China has been successfully deployed for the first time in Hong Kong to treat a man with myeloma,…
Phase 3 CLL/SLL trial of ICP-248 plus orelabrutinib doses first patient
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
Cabometyx wins FDA approval for treating certain pancreatic cancers
The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of…
Glioblastoma trial of VXM01 plus Bavencio shows promising safety
Combining VXM01, an experimental anticancer vaccine, with Bavencio (avelumab), which activates the immune system to attack cancer cells, was well tolerated in a…
Nemvaleukin plus Keytruda fails in Phase 3 trial in ovarian cancer
Interim data from a Phase 3 trial failed to show that a combination of nemvaleukin, an experimental immune-modulating therapy, and Keytruda (pembrolizumab) could outperform standard…
Personalized cancer vaccine shows potential in myeloma, solid tumors
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a…
Orca-T outperforms standard stem cell transplant for blood cell cancer
Orca-T, Orca Bio‘s investigational allogeneic stem cell transplant for treating blood cell cancers, more than doubled the rate of survival free from moderate…
FDA grants orphan drug status to PEP-010 for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Pep-Therapy‘s PEP-010, a potential first-in-class treatment for pancreatic cancer. The…
Repurposed avapritinib reduced tumor size in hard-to-treat gliomas
Avapritinib, an approved orally available medication, reduced tumor size in a subset of children and young adults with treatment-resistant high-grade gliomas, a study shows.
